{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:52:26Z","timestamp":1781844746873,"version":"3.54.5"},"reference-count":34,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Shan Dong Provincial Medical Association","award":["No. YXH2024ZS007"],"award-info":[{"award-number":["No. YXH2024ZS007"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The efficacy and safety of adebrelimab plus carboplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) have been investigated in the CAPSTONE-1 study. However, many patients with brain metastases, as well as some with liver metastases and pleural effusion, were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The present study focuses on exploring the safety and efficacy of adebrelimab in these patients in the real world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This was a multicenter, prospective, observational, real-world study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with ES-SCLC and brain metastases, liver metastases, or pleural effusion who were willing to receive adebrelimab-based regimens as first-line therapy were enrolled. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate, disease control rate, duration of response, overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Between March 2, 2023, and September 3, 2024, a total of 149 patients were enrolled in the present study. Among them, 50 (33.6%) patients had brain metastasis, 60 (40.3%) had liver metastasis, and 85 (57.0%) had pleural effusion. At data cutoff (May 5, 2025), the median PFS (mPFS) was 6.47\u2009months (95% confidence interval (CI): 5.85\u20137.03), and the median OS (mOS) was 13.77\u2009months (95%CI: 11.30\u201315.44) in the full analysis set. Additionally, the mPFS were 6.01\u2009months (95%CI: 4.83\u20137.59), 5.45\u2009months (95%CI: 4.30\u20136.51\u2009months), and 6.60\u2009months (95%CI: 5.29\u20137.59\u2009months) in patients with brain metastases, liver metastases, and pleural effusion, respectively. The mOS were 13.77\u2009months (95%CI: 9.67\u201322.90\u2009months), 10.51\u2009months (95%CI: 8.38\u201313.44\u2009months), and 12.85\u2009months (95%CI: 9.20\u201316.39\u2009months) in patients with brain metastases, liver metastases, and pleural effusion, respectively. Grade \u2a7e3 treatment-emergent adverse events occurred in 63 (42.3%) patients. No new safety signals were found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Adebrelimab-based regimens showed effectiveness comparable to clinical trials in special populations such as patients with brain metastases or pleural effusion, and demonstrated an acceptable safety profile. However, the benefit appeared limited in patients with liver metastases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261458300","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:17:41Z","timestamp":1781673461000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adebrelimab-based regimens as first-line treatment for ES-SCLC in specific populations: a real-world study in Chinese patients"],"prefix":"10.1177","volume":"18","author":[{"given":"Liyang","family":"Jiang","sequence":"first","affiliation":[{"name":"Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6349-1191","authenticated-orcid":false,"given":"Junxu","family":"Wen","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangbing","family":"Xu","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Meng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Shandong First Medical University, Tai\u2019an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nailiang","family":"Zhai","sequence":"additional","affiliation":[{"name":"Binzhou Medical College Affiliated Hospital, Binzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Shao","sequence":"additional","affiliation":[{"name":"Qilu Hospital, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peizhu","family":"Wu","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaikai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Kong","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Peng","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjiao","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00312-3"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.87"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13412"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12218"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01435"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0002"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_3_4_12_2","first-page":"365","article-title":"Adebrelimab in small cell lung cancer: from current advances to emerging combination strategy and challenge","volume":"19","author":"Yang H","year":"2025","unstructured":"Yang H, Yang L, Liu Y, et al. Adebrelimab in small cell lung cancer: from current advances to emerging combination strategy and challenge. Biologics 2025; 19: 365\u2013377.","journal-title":"Biologics"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00261-6"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0560"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015142388"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-023-00228-w"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197911)44:5<1885::AID-CNCR2820440550>3.0.CO;2-F"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830201)51:3<529::AID-CNCR2820510327>3.0.CO;2-0"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102871"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100783"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03387-7"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.096"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.09.027"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2024-1091"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.01.030"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70256"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000499372"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2542434"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108758"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14417-0"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro6.70043"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261458300","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261458300","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261458300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:16:12Z","timestamp":1781842572000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261458300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"alternative-id":["10.1177\/17588359261458300"],"URL":"https:\/\/doi.org\/10.1177\/17588359261458300","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"17588359261458300"}}